X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
hema5 (54) 54
humans (53) 53
oncology (52) 52
index medicus (51) 51
original reports (48) 48
male (46) 46
female (45) 45
middle aged (39) 39
aged (38) 38
adult (33) 33
treatment outcome (31) 31
aged, 80 and over (25) 25
adolescent (21) 21
antineoplastic combined chemotherapy protocols - therapeutic use (20) 20
young adult (18) 18
disease-free survival (16) 16
hema6 (15) 15
leukemia, myeloid, acute - drug therapy (13) 13
therapy (13) 13
drug administration schedule (12) 12
time factors (12) 12
child (11) 11
kaplan-meier estimate (11) 11
remission induction (11) 11
recurrence (10) 10
risk factors (10) 10
acute myelogenous leukemia (9) 9
antineoplastic combined chemotherapy protocols - adverse effects (9) 9
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (9) 9
age factors (8) 8
cancer (8) 8
cytarabine - administration & dosage (8) 8
dose-response relationship, drug (8) 8
follow-up studies (8) 8
hema7 (8) 8
imatinib mesylate (8) 8
leukemia, lymphocytic, chronic, b-cell - drug therapy (8) 8
leukemia, myeloid, acute - mortality (8) 8
pedi2 (8) 8
prognosis (8) 8
risk assessment (8) 8
survival rate (8) 8
acute myeloid-leukemia (7) 7
antineoplastic agents - administration & dosage (7) 7
antineoplastic agents - therapeutic use (7) 7
benzamides (7) 7
bone1 (7) 7
hema13 (7) 7
hema8 (7) 7
hema9 (7) 7
risk (7) 7
rituximab (7) 7
bios3 (6) 6
child, preschool (6) 6
faze (6) 6
hematopoietic stem cell transplantation (6) 6
leukemia, myeloid, acute - genetics (6) 6
mutation (6) 6
myelodysplastic syndromes - drug therapy (6) 6
protein kinase inhibitors - administration & dosage (6) 6
survival analysis (6) 6
antineoplastic agents - adverse effects (5) 5
chemotherapy (5) 5
drug resistance, neoplasm (5) 5
hema3 (5) 5
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (5) 5
precursor cell lymphoblastic leukemia-lymphoma - genetics (5) 5
pyrimidines - adverse effects (5) 5
pyrimidines - therapeutic use (5) 5
retrospective studies (5) 5
survival (5) 5
trial (5) 5
united states (5) 5
vidarabine - administration & dosage (5) 5
vidarabine - analogs & derivatives (5) 5
administration, oral (4) 4
aml (4) 4
arabinonucleosides - administration & dosage (4) 4
cells (4) 4
chronic myelogenous leukemia (4) 4
cohort studies (4) 4
cyclophosphamide (4) 4
cytogenetics (4) 4
dasatinib (4) 4
daunorubicin - administration & dosage (4) 4
follow-up (4) 4
genetic predisposition to disease (4) 4
idarubicin - administration & dosage (4) 4
infant (4) 4
maximum tolerated dose (4) 4
mitoxantrone (4) 4
piperazines - administration & dosage (4) 4
piperazines - adverse effects (4) 4
piperazines - therapeutic use (4) 4
polymerase chain reaction (4) 4
proportional hazards models (4) 4
pyrimidines - administration & dosage (4) 4
regimen (4) 4
review (4) 4
review articles (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2011, Volume 29, Issue 33, pp. 4417 - 4423
Purpose Outcome in acute myeloid leukemia (AML) worsens with age, at least in part because of higher treatment-related mortality (TRM) in older patients.... 
SURVIVAL | AML | TRIALS | INTENSIVE CHEMOTHERAPY | OLDER PATIENTS | ONCOLOGY | RECOMMENDATIONS | PROGNOSTIC MODELS | BLAST CLEARANCE | CYTOGENETICS | AGE | Age Factors | Humans | Middle Aged | Induction Chemotherapy | Male | Risk | Leukemia, Myeloid, Acute - mortality | Time Factors | Adolescent | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Aged | Original Reports | Hema5
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2015, Volume 33, Issue 11, pp. 1235 - 1242
Journal Article
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2009, Volume 27, Issue 31, pp. 5175 - 5181
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2010, Volume 28, Issue 14, pp. 2381 - 2388
Purpose There is a considerable variability in the level of molecular responses achieved with imatinib therapy in patients with chronic myeloid leukemia (CML).... 
OCT-1 ACTIVITY | THERAPY | CHRONIC-PHASE | ONCOLOGY | KINASE DOMAIN MUTATIONS | STANDARD-DOSE IMATINIB | SUBOPTIMAL RESPONSE | NONADHERENCE | DETERMINANT | CML PATIENTS | BCR-ABL TRANSCRIPTS | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Antineoplastic Agents - therapeutic use | RNA, Messenger - metabolism | Young Adult | Time Factors | Aged, 80 and over | Adult | Drug Monitoring - instrumentation | Female | Antineoplastic Agents - pharmacokinetics | Micro-Electrical-Mechanical Systems - instrumentation | Cytogenetic Analysis | Piperazines - pharmacokinetics | Protein Kinase Inhibitors - pharmacokinetics | Risk Assessment | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Logistic Models | Treatment Outcome | Octamer Transcription Factor-1 - genetics | Piperazines - therapeutic use | Gene Expression Regulation, Leukemic | Imatinib Mesylate | ATP Binding Cassette Transporter, Subfamily B | ATP Binding Cassette Transporter, Subfamily B, Member 1 - genetics | Polymorphism, Genetic | Fusion Proteins, bcr-abl - genetics | Medication Adherence | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - pharmacokinetics | Aged | Benzamides | Mutation | Hema7 | ORIGINAL REPORTS | Hema5
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article